Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pelthos Therapeutics (PTHS) EPS (Weighted Average and Diluted) (2024 - 2025)

Pelthos Therapeutics has reported EPS (Weighted Average and Diluted) over the past 2 years, most recently at -$11.52 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$11.52 for Q4 2025, down 233.44% from a year ago — trailing twelve months through Dec 2025 was -$11.52 (down 233.44% YoY), and the annual figure for FY2025 was -$23.04, down 61.46%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$11.52 at Pelthos Therapeutics, down from -$5.3 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for PTHS hit a ceiling of -$0.32 in Q1 2025 and a floor of -$11.52 in Q4 2025.